Project Grant R44AG066386

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) will support the development of a targeted nanoformulation delivery system for the bioactive curcuminoids curcumin and bisdemethoxycurcumin to treat Alzheimer's disease. The $1,006,428 award to 3P Biotechnologies, Inc. will fund research to optimize exosome-based formulations of these compounds and evaluate their efficacy and biodistribution in animal models of Alzheimer's disease. The delivery...

This $949,062 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Somatoceutics LLC aims to develop a novel, non-toxic nanomaterial for delivering drugs across the blood-brain barrier to treat Alzheimer's disease and related dementias. The key objectives are to: Optimize and standardize the assembly of SMC-101 nanotubes, a natural peptide-based nanomaterial, to load with drugs and demonstrate their ability to transcytose the blood-brain barrier in vitro....

This $843,806 Cooperative Agreement award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop and evaluate blood-brain barrier (BBB) crossing lipid nanoparticles (BLNPs) for efficient delivery of nucleic acid-based therapeutics to the brain. The project, led by the Icahn School of Medicine at Mount Sinai (ISMMS), seeks to synthesize and...

This Project Grant award of $835,417, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to develop novel lipid nanoparticle (LNP) formulations to efficiently deliver nucleic acid therapeutics across the blood-brain barrier for the treatment of Alzheimer's disease (AD). The key objectives include: Synthesizing novel blood-brain barrier-crossing lipids and formulating a library of LNPs to optimize their trafficking across the blood-brain barrier. Engineering siRNA...

This Project Grant award, with a total funding amount of $4,619,796.00, was provided by the National Institute on Aging under the Aging Research program (CFDA 93.866). The grant was awarded to the Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences), a non-profit research organization located in Augusta, Georgia. The purpose of this grant is to investigate the use of noninvasive pulsed laser therapy as a potential therapeutic approach for brain protection in...

This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model. If the initial feasibility is established, the company plans to...

This Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) supports research to determine whether craniosynostosis, a skull disorder, is a risk factor for Alzheimer's disease (AD) and to investigate the use of multiplex approaches to activate brain lymphatics as a potential therapeutic treatment for AD. The $207,500 award to the University of Southern California will fund studies to: 1) examine the relationship between craniosynostosis...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $805,738 in funding to the Battelle Memorial Institute's Pacific Northwest National Laboratory Division, operating as Pacific NW National, to conduct research on the role of brain lipoproteins in the development of Alzheimer's disease. The key objectives of this 5-year project are to: 1) assess the impact of different apolipoprotein E (ApoE) isoforms on the distribution, composition, and...

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $4,694,672 to North Dakota State University from May 15, 2021 through April 30, 2024. The funding supports research to design a non-viral gene delivery system for delivering an APOE2 plasmid to the brain. Specifically, the university will synthesize and characterize liposomal nanoparticles loaded with chitosan-APOE2 polyplexes and modified with transferrin and cell-penetrating peptides...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $426,250 to Wake Forest University Health Sciences to develop and evaluate a novel positron emission tomography (PET) radiotracer, [11C]TM-N1324, to image the GPR39 receptor in Alzheimer's disease (AD). The project aims to: 1) investigate the imaging utility of [11C]TM-N1324 in rodent models overexpressing or lacking GPR39, as well as in an AD transgenic mouse model, correlating PET outcomes...